Targeting the 'Undruggable' Driver Protein, KRAS<sup>G12D</sup>, as Potential Therapy in Prostate Cancer.
Kargbo RB.
In spite of the progress made in the development of KRAS<sup>G12C</sup> inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRAS<sup>G12D</sup> for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.